RELMADA THERAPEUTICS, INC.
RLMD · XNASCIK 1553643fmd_1TPEDSD1WCA743C4KRYHCF5QWVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2005 to Sep 30, 2026, 72 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | – |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Net interest income | 0 | (0) | (1) | 0 | 1 | 1 | 3 | 5 | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | (0) | (1) | (1) | (4) | 0 | (0) |
| Research and development | 6 | 1 | 3 | 8 | 36 | 91 | 113 | 55 | 46 | 27 |
| Total operating expenses | 16 | 7 | 7 | 15 | 61 | 126 | 161 | 104 | 84 | 59 |
| Operating income | (16) | (7) | (7) | (15) | (61) | (126) | (161) | (104) | (84) | (59) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | 0 | 2 | 5 | 4 | 1 |
| Other non-operating income (expense) | 13 | 1 | (2) | 0 | 1 | (0) | 4 | 5 | 4 | 2 |
| Net income from continuing operations | – | – | – | – | (59) | (126) | – | – | – | – |
| Net income | (3) | (6) | (9) | (15) | (59) | (126) | (157) | (99) | (80) | (57) |